The Live Mint – It’s Biocon’s day in the sun
Economic Times – US FDA Panel Nod for Biocon Breast Cancer Drug Biosimilar
May 2017
The Times of India – US institute honours Kiran with award for excellence
The Business Standard – ‘We need a system which provides quality drugs at low cost’ Interview with Ms. Shaw
April 2017
Business Standard – Biocon Q4 profits up 75% to Rs 135-Cr
Times of India – Biocon set to issue bonus shares 2:1; revenue flat in Q4
March 2017
The Hindu Business Line – Our biologics business is expected to continue on its strong growth trajectory
Business Standard – For Biocon, Windfall seen from drug launch
Bloomberg International – Biocon’s strong positioning in the area of Biosimilars and robust pipeline.
Corporate Citizen – Healing The World
February 2017
The Financial Express – USFDA accepts Biocon’s drug application for review
The Live Mint – We expect Malaysia unit to break even next year
January 2017
The Financial Express – Biocon Limited: Strong quarter, positive trends
Economic Times – Tech based patient tracking to make its debut in state
ET Health World – Biocon aims for the highest quality in the lowest cost
The Live Mint – Biocon Q3: All eyes on pot at the end of rainbow
The Live Mint – ‘We expect a turnaround in branded formulations in FY18’
The Hindu Business Line – Biocon bags Rs 460-cr contract from Malaysia
Business Standard – In Biocon, investors sees a blockbuster pipeline
The Financial Express – Biocon a leading Indian play on global biosimilar scene
The Live Mint – Market opportunity for trastuzumab is $7 billion
Economic Times – Biocon has little room to slip up after strong 2016
The Times of India – These graduates aim to take Biotech to another level